-+ 0.00%
-+ 0.00%
-+ 0.00%

On November 22, Oncternal Therapeutics Announced That Nasdaq Plans To Delist Its Stock On December 3, Nasdaq Classified The Company As "Public Shell," Following Its Decision To Lay Off Employees And Explore Strategic Alternatives-Filing

Benzinga·11/25/2024 11:30:45
Listen to the news

Nasdaq will file a delisting notice with the SEC. Oncternal has stated it will not appeal the decision.